applied this approach for Cystic Fibrosis (CF) therapy, employing nanoparticles to deliver triplex‐forming PNA molecules for gene editing of F508 gene deletion.[115] They encapsulated tail‐clamp PNAs and donor DNA molecules in PLGA/PBAE‐based nanoparticles coated with Model Peptide carrier peptide (MPG) to correct the F508 in CFTR mutation both in vitro in human bronchial epithelial (HBE) cells and in vivo in a CF murine model. Here, CFTR is linked to cystic fibrosis.